GSK Initiates Development Of New Candidate Vaccine For H1N1 Influenza Vaccine
Vaccine expected to be available in four-to-six months time
With WHO raising the current level of influenza pandemic alert from phase 5 to phase 6, GSK has initiated development of a new candidate vaccine for A (H1N1) influenza virus. WHO has stated in their current assessment of the situation that this pandemic is currently of a moderate severity.
In addition to increasing production and supply of the anti-viral medication, Relenza (zanamivir), the company continues to focus efforts on the development of a candidate A(H1N1) adjuvanted influenza vaccine.
After the first step for manufacturing an influenza vaccine to prepare the seed strain for production, the company will start production of the new candidate A (H1N1) influenza vaccine. The first doses of the A (H1N1) vaccine antigen are expected to be available in four to six months time, subject to regulatory approval.
Related Insight
Suppliers Directory
Presspart - Metal and Plastic Drug Delivery Components and Devices
Presspart specialises in bespoke, concept-to-completion, metal and plastic drug delivery components and devices that help pharmaceutical companies deliver drugs of the present and future. With more than 40 years' experience and a worldwide reputation for competence, quality and innovation, Presspart constantly studies, refines and optimises its processes to ensure optimum quality and performance for its customers.
Suppliers
Sotax - Solutions for Pharmaceutical Testing
SOTAX, founded in 1973 in Switzerland, is a fast-growing group leader in providing high-quality dissolution testing systems, composite assay and content uniformity workstations and physical tablet testing instruments for the pharmaceutical industry throughout the world.
Suppliers
Logopharm - Membrane Proteomics
LOGOPHARM GmbH provides specialised services in proteomic target and biomarker R&D with a strong focus on membrane proteins and antibodies.
Suppliers
Farmalyse - Laboratory Contract Services
Farmalyse is a contract service provider for the pharmaceutical industry, hospitals and the medical device industry offering a full range of laboratory investigation services, quality control testing, analytical method development-validation and comprehensive and customised international services which focus on import, release and supply chain management.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Efficacy and Surgical Research Services (ESRS)
Published by Toxikon Europe
Contract Research & Services > Contract Research > White Papers
Sample Preparation in Wildlife Forensics
Published by Genevac
White Papers
Pressure Mounts for Patient Access to Investigational Drugs
Published by CenterWatch
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.